Eli Lilly & Company

Type: Company
Name: Eli Lilly & Company (Eli Lilly and Company)
First reported 10 hours ago - Updated 10 hours ago - 1 reports

Eli Lilly (LLY) Breaks Through Resistance at $65.11

Shares of Eli Lilly (NYSE:LLY) opened today above their pivot of $64.44 and have already reached the first level of resistance at $65.11. Should the shares continue to rise, the resistance pivots of $65.86 and $67.28 will be of interest. ... [Published Individual.com - 10 hours ago]
First reported 12 hours ago - Updated 12 hours ago - 1 reports

Eli Lilly (LLY) Earnings Report: Q3 2014 Conference Call Transcript

, 09:00 AM ET. This is a transcript of that earnings call: Company Participants John Lechleiter; Eli Lilly; Chairman, CEO and President Phil Johnson; Eli Lilly; VP of Investor Relations Derica Rice; Eli Lilly; CFO, EVP of Global Enrique Conterno; ... [Published Lebanon Daily News - 12 hours ago]
First reported 13 hours ago - Updated 13 hours ago - 1 reports

ModernGraham Quarterly Valuation Of Eli Lilly & Co.

Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: NEXT ARTICLE More From BioPortfolio on "ModernGraham Quarterly Valuation Of Eli Lilly & Co." Search BioPortfolio:Loading ... [Published BioPortfolio - 13 hours ago]
First reported 14 hours ago - Updated 14 hours ago - 1 reports

Lilly, Zymeworks Expand Strategic Licensing and Collaboration Agreement

Zymeworks Inc. and Eli Lilly and Company are expanding their existing licensing and collaboration agreement. ... [Published Technology Networks - 14 hours ago]
First reported Oct 24 2014 - Updated 14 hours ago - 3 reports

Eli Lilly's Q3 Earnings In-Line but Generics Hit Revenues

Eli Lilly & Company ( LLY ) reported third-quarter 2014 adjusted earnings per share of 66 cents, in line with the Zacks Consensus Estimate but 41% below the year-ago earnings.[embedded content] Eli Lilly And Company - Earnings Surprise | FindTheBes ... [Published Yahoo! Finance - 14 hours ago]
First reported Oct 23 2014 - Updated 19 hours ago - 12 reports

Lacklustre sales hit Lilly again

Lilly is enduring one of the bleakest financial years in its history as patent expiries continue to take chunks out of its balance sheet.In its latest third quarter results Lilly says its sales were down an eye-watering 16% to $4.85 billion, with much ... [Published Pharmafocus - 19 hours ago]
First reported Oct 23 2014 - Updated Oct 23 2014 - 2 reports

Eli Lilly/Boehringer's Diabetes Drug Under FDA Review - Analyst Blog

The companies are looking to get the Jardiance/metformin fixed-dose combination approved for the treatment of type II diabetes in adult patients.We remind investors that Jardiance was approved by the FDA in Aug 2014 as an adjunct to diet and exercise ... [Published Nasdaq - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 3 reports

Stock Market Today: Stocks Surge as Caterpillar and GM Top Estimates

10/23/14 - 08:47 AM EDTNEW YORK ( TheStreet ) -- Stock futures in the U.S. were rising on better-than-forecast manufacturing data from China and the eurozone, and stronger-than-expected earnings from U.S. economic bellwethers Caterpillar ( CAT ) and ... [Published TheStreet.com - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

Eli Lilly posts 3Q earnings miss

Earnings HQ: FBN’s Lori Rothman breaks down Eli Lilly’s third-quarter earnings report. ... [Published FOX Business - Video - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 8 reports

Eli Lilly Hit By Patent Expirations, Prescription Volume Plunges

Related Biotechnology, Pharmaceutical and Healthcare NewsOriginal Article: NEXT ARTICLE More From BioPortfolio on "Eli Lilly Hit By Patent Expirations, Prescription Volume Plunges" Search BioPortfolio:Loading ... [Published BioPortfolio - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 1 reports

How Will Eli Lilly (LLY) Stock Be Affected Today By Its Mixed Earnings Report?

10/23/14 - 09:45 AM EDTNEW YORK ( TheStreet ) -- Eli Lilly ( LLY )  shares are down 1.05% to $64 in early market trading on Wednesday after the company reported a 58% drop in third quarter income from the previous year and fell short of analysts expectations ... [Published TheStreet.com - Oct 23 2014]
First reported Oct 23 2014 - Updated Oct 23 2014 - 2 reports

UPDATE: Eli Lilly Posts Lower Q3 Profit

Eli Lilly & Co (NYSE: LLY) reported a drop in its third-quarter earnings. The Indianapolis, Indiana-based company posted quarterly ... ... [Published Town Hall - Oct 23 2014]

Quotes

John Lechleiter, chief executive of Eli Lilly, told CNBC’s Squawk Box show: "Even though our sales were down 16% this quarter, if you take out the two big patent losses we had in the last year, our underlying sales growth was 7%  and most of that was from volume.”"
...The provision states: "It shall not be an act of infringement to make, use, or sell a patented invention … solely for uses reasonably related to the development and submission of information under a Federal law which regulates the manufacture, use, or sale of drugs." The Federal Food, Drug, and Cosmetic Act (FDCA) is one such federal law, which requires drugmakers to submit research data to the FDA and receive regulatory...
"What we don't know is how much amyloid-beta lowering is the right number and what should we be shooting for" he says

More Content

All (1766) | News (1298) | Reports (0) | Blogs (417) | Audio/Video (0) | Fact Sheets (18) | Press Releases (29)
sort by: Date | Relevance
Quality cottage in Cork’s Dunderrow worth viewi... [Published Irish Examiner - 3 hours ago]
Trulicity One-Weekly GLP-1 Shipping Now [Published Diabetes in Control - 4 hours ago]
HMN and PM360 Hold 1st Annual DTP Conference [Published PM 360 - 6 hours ago]
Why Highbridge Capital sells stake in FirstEner... [Published Yahoo! Finance - 6 hours ago]
Why Highbridge Capital exits its stake in Celge... [Published Yahoo! Finance - 9 hours ago]
Eli Lilly (LLY) Breaks Through Resistance at $6... [Published Individual.com - 10 hours ago]
Eli Lilly (LLY) Earnings Report: Q3 2014 Confer... [Published Lebanon Daily News - 12 hours ago]
ModernGraham Quarterly Valuation Of Eli Lilly &... [Published BioPortfolio - 13 hours ago]
Lilly, Zymeworks Expand Strategic Licensing and... [Published Technology Networks - 14 hours ago]
Eli Lilly and Earns AA Credit Rating (LLY) [Published American Banking News - 14 hours ago]
Eli Lilly's Q3 Earnings In-Line but Generics Hi... [Published Yahoo! Finance - 14 hours ago]
United Way Day of Caring is Nov. 1 [Published Batesville Herald Tribune - 15 hours ago]
Eli Lilly hit by patent expirations on Cymbalta... [Published Pharma Letter - 15 hours ago]
Eli Lilly (LLY) Trading Near $63.02 Support Level [Published MarketIntelligenceCenter.com - 15 hours ago]
Enterprise M3 sets out roadmap for delivery of ... [Published Basingstoke Gazette - 16 hours ago]
Lacklustre sales hit Lilly again [Published Pharmafocus - 19 hours ago]
Commerce Secretary speaks in Korea [Published Asian American Press - 19 hours ago]
Zymeworks, Lilly extend deal for new bi-specifi... [Published PBR - News - 20 hours ago]
Eli Lilly and's (LLY) CEO John Lechleiter on Q3... [Published Seeking Alpha - Oct 24 2014]
Acrux reports Q3 Axiron sales of $US36M [Published Melbourne Age - Oct 24 2014]
Evolution of the Patent Infringement Safe Harbor [Published Corporate Counsel - Oct 24 2014]
Boehringer, Vitae survive first clinical challe... [Published FierceBiotech - Oct 23 2014]
West Coast Biotech Roundup: Genentech, Sutro, A... [Published Xconomy - Oct 23 2014]
Eli Lilly/Boehringer's Diabetes Drug Under FDA ... [Published Nasdaq - Oct 23 2014]
The Top Ten Stocks for Oct. 23 [Published Bloomberg - Oct 23 2014]
Stock Market Today: Stocks Pare Sharp Gains Ahe... [Published Colchester Bulletin - Oct 23 2014]
Eli Lilly/Boehringer's Diabetes Drug Under FDA ... [Published Zacks.com - Oct 23 2014]
UPDATE: Microsoft, Amazon.com results after hours [Published Morningstar.com - Oct 23 2014]
Stock Market Today: Stocks Pare Sharp Gains Ahe... [Published TheStreet.com - Oct 23 2014]
Eli Lilly and (LLY) Releases Quarterly Earnings... [Published American Banking News - Oct 23 2014]
1 2 3 4 5 6 7 8 9 10 ...
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Eli Lilly (LLY) Trading Near $63.02 Support Level [Published MarketIntelligenceCenter.com - 15 hours ago]
After Thursday’s trading in Eli Lilly and Co (LLY) MarketIntelligenceCenter.com's patented algorithms uncovered a trade that offers a 2.59% return or 16.57% on an annualized basis (for comparison purposes only), while providing 1.54% downside protection. ...
Zymeworks, Lilly extend deal for new bi-specifi... [Published PBR - News - 20 hours ago]
Zymeworks and Eli Lilly and Company have extended their existing licensing and collaboration agreement for development of an undisclosed number of new bi-specific antibody therapeutics using Zymeworks’ Azymetric platform. ...
List of banks that will support Apple Pay in co... [Published 9 to 5 Mac - Oct 23 2014]
Visa has published a list of banks and financial institutions that will support Apple Pay in the United States ‘in the coming weeks’, while Mastercard has it’s own list of supported banks arriving in the coming months. The mobile payments service ...
Eli Lilly CEO: We hope to resume growth next year [Published FOX Business - Video - Oct 23 2014]
Eli Lilly CEO John Lechleiter discusses his outlook for growth and when he expects to have patent expirations behind. ...
Stock futures surging; 7.8 million cars targete... [Published Business - cleveland.com - Oct 23 2014]
Also, Asian stocks fell and gold prices inched lower; Melanie Healey leaving as head of Procter & Gamble's North American business; Eli Lilly quarterly earnings plunge 58 percent; Mark Zuckerberg tells Chinese students in Chinese that Facebook is hiring ...
1 2 3 4 5 6 7 8 9 10 ...

Press Releases

sort by: Date | Relevance
Lilly Reports Third-Quarter 2014 Results [Published Financial Services - Oct 23 2014]
Lilly Declares Fourth-Quarter 2014 Dividend [Published Financial Services - Oct 20 2014]
Acquisitions, Senior Level Promotions, Public O... [Published Financial Services - Sep 29 2014]
Scanning Pharma Equities - Novo Nordisk, Teva P... [Published Financial Services - Sep 26 2014]
Lilly and AstraZeneca announce alliance to co-d... [Published Financial Services - Sep 16 2014]
1 2 3 4 5 6
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.